Slotnik Capital LLC Takes $2.59 Million Position in Kenvue Inc. $KVUE

Slotnik Capital LLC bought a new position in Kenvue Inc. (NYSE:KVUE) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 150,000 shares of the company’s stock, valued at approximately $2,588,000. Kenvue accounts for 0.6% of Slotnik Capital LLC’s investment portfolio, making the stock its 23rd biggest holding.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. USS Investment Management Ltd lifted its position in Kenvue by 11.4% in the fourth quarter. USS Investment Management Ltd now owns 395,958 shares of the company’s stock worth $6,840,000 after purchasing an additional 40,372 shares during the period. Whetstone Capital Advisors LLC increased its stake in shares of Kenvue by 7.3% in the fourth quarter. Whetstone Capital Advisors LLC now owns 13,463 shares of the company’s stock valued at $232,000 after buying an additional 919 shares in the last quarter. Yakira Capital Management Inc. acquired a new stake in shares of Kenvue in the fourth quarter valued at $826,000. Vanguard Personalized Indexing Management LLC increased its stake in shares of Kenvue by 11.9% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 212,574 shares of the company’s stock valued at $3,667,000 after buying an additional 22,614 shares in the last quarter. Finally, Venture Visionary Partners LLC acquired a new stake in Kenvue in the fourth quarter worth about $426,000. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Performance

KVUE opened at $18.25 on Tuesday. The business has a fifty day simple moving average of $17.45 and a 200 day simple moving average of $17.55. The company has a market capitalization of $35.03 billion, a PE ratio of 21.47, a price-to-earnings-growth ratio of 1.38 and a beta of 0.54. Kenvue Inc. has a 1 year low of $14.02 and a 1 year high of $22.87. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.05. The business had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The firm’s quarterly revenue was up 4.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.24 EPS. Research analysts expect that Kenvue Inc. will post 1.16 EPS for the current year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th were issued a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a dividend yield of 4.5%. The ex-dividend date of this dividend was Wednesday, May 13th. Kenvue’s dividend payout ratio is 97.65%.

Insider Activity

In other news, General Counsel Matthew Orlando sold 38,491 shares of the stock in a transaction on Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 1.59% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on the company. Barclays lowered their price objective on Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 14th. Zacks Research upgraded Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, May 8th. Weiss Ratings cut Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, May 29th. UBS Group cut their target price on Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 7th. Finally, Citigroup cut their target price on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 15th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and twelve have given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $19.33.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.